共 54 条
- [3] A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens [J]. INVESTIGATIONAL NEW DRUGS, 2011, 29 (05) : 1021 - 1028
- [9] AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases:: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models [J]. MOLECULAR CANCER THERAPEUTICS, 2007, 6 (08) : 2209 - 2219